Financial and counseling support for transgender women to improve health services access
Economic Navigation and Strengthening to Research Unrestricted Services for Transgender Women (ENTRUST)
This study tests whether financial help and personalized counseling can make it easier for transgender women to access substance use services and HIV prevention methods like PrEP.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 110 (estimated) |
| Ages | 18 Years and up |
| Sex | Male |
| Sponsor | University of Central Florida Academic / other |
| Locations | 1 site (Orlando, Florida) |
| Trial ID | NCT06202898 on ClinicalTrials.gov |
What this trial studies
This study aims to explore how financial stabilization and tailored counseling can enhance the likelihood of transgender women accessing substance use services and pre-exposure prophylaxis (PrEP) if they are HIV-negative. It addresses the critical gap in understanding the relationship between substance use disorders and adherence to antiretroviral treatment (ART) among transgender women. By focusing on this vulnerable population, the study seeks to improve engagement in HIV prevention initiatives and treatment adherence, ultimately contributing to better health outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are transgender women aged 18 and older who are not consistently using PrEP and can communicate in English or Spanish.
Not a fit: Patients with life-threatening substance use disorders or those unable to adhere to study procedures may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve health service access and treatment adherence for transgender women, reducing HIV transmission rates.
How similar studies have performed: While there is limited literature specifically addressing this approach, similar studies have shown promise in improving health outcomes for marginalized populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Aged ≥18 years * Male at birth * Identify as a woman/transgender woman * Should not be consistently using PrEP (less than four doses per week) * Should not have any known allergy or adverse reaction to PrEP or the active drug tenofovir in ART. One of the goals of the study is to move more people into a PrEP program * Be able to speak and understand spoken English and/or Spanish (including persons who cannot read or write) * Have a smart phone that can take pictures Exclusion Criteria: * Unwilling to adhere to study procedures * Participation in an HIV vaccine trial * Have a life-threatening SUD\* * Any condition, that in the opinion of the study staff, would make participation in the study unsafe, or interfere with achieving the study objective such as medical conditions which prevents the use of PrEP * Unable to provide consent
Where this trial is running
Orlando, Florida
- University of Central Florida — Orlando, Florida, United States (Recruiting)
Study contacts
- Principal investigator: Elena Cyrus, PhD — University of Central Florida
- Study coordinator: Elena Cyrus, PhD
- Email: elena.cyrus@ucf.edu
- Phone: 4072661507
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.